News
Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 10 years ago, it would be worth $8,899.40 today based on a price of $781.99 for LLY at the time of writing.
Shares of Johnson & Johnson climbed 6.8% in morning trading, enough to pace the S&P 500 index's SPX gainers. They were also headed for their biggest one-day gain and best postearnings reaction since ...
Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's policies. Health care stocks can often be a solid defensive play in an ...
Johnson & Johnson beat quarterly sales expectations and is raising its outlook for the year, despite the threat of increased tariffs on the pharmaceutical industry.
Eli Lilly’s stock closed at $771.75, slipping 3.45% and lagging the broader market. The company’s shares fell despite outperforming the medical sector over the past month. Analysts eagerly await its ...
4h
Zacks Investment Research on MSNJohnson & Johnson (JNJ) Q2 Earnings and Revenues Top EstimatesJohnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.82 per share a year ago. These ...
5h
Zacks Investment Research on MSNJohnson & Johnson (JNJ) Surpasses Q2 Earnings and Revenue EstimatesJohnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.82 per share a year ago. These ...
Alright, listen to me. This one is one that everyone’s going to give up on. Then one day, it’s going to be up 300, I’m not ...
Currently, Nvidia accounts for nearly 8 percent of the S&P 500. That’s the highest weighting for a single stock in 45 years, according to Todd Sohn, senior ETF strategist at Strategas Securities. For ...
The life expectancy has increased in the U.S. and worldwide, contributing to healthcare companies retaining their patients ...
Lilly, Johnson & Johnson, AbbVie, Pfizer and more pharma stocks shrug even amid Trump's fresh pharma tariff threats.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results